Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 30

Results For "prescription"

326 News Found

U.S. FDA accepts Bristol Myers Squibb’s application for Deucravacitinib
Biotech | November 30, 2021

U.S. FDA accepts Bristol Myers Squibb’s application for Deucravacitinib

Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla (apremilast)


Obseva announces U.S. FDA acceptance of new drug application for linzagolix
Biotech | November 23, 2021

Obseva announces U.S. FDA acceptance of new drug application for linzagolix

Obseva announced previously that the company has entered into a partnership with Syneos Health to support commercialization of linzagolix in the US and EU


U.S. FDA grants breakthrough designation to Datar’s blood test to detect breast cancer
Drug Approval | November 20, 2021

U.S. FDA grants breakthrough designation to Datar’s blood test to detect breast cancer

It is the first blood test able to detect early-stage Breast Cancer with high accuracy in women above the age of 40 years


Indian nutraceutical market is expected to touch US $ 18 bn by 2025: Dr R.B Smarta
interviews | November 18, 2021

Indian nutraceutical market is expected to touch US $ 18 bn by 2025: Dr R.B Smarta

The nutraceutical sector is on the cusp of exponential growth and Covid-19 has accelerated the pace of its applications. Dr R.B Smarta, CMD, Interlink, shares his perspective on the growth opportunities and challenges for the sector


U.S FDA authorises EaseVRx, immersive virtual reality for pain relief
Drug Approval | November 17, 2021

U.S FDA authorises EaseVRx, immersive virtual reality for pain relief

EaseVRx employs the principles of cognitive behavioural therapy and other behavioural therapy techniques for the reduction of pain and pain interference


DawaDost rolls out diabetes medicine at Re 1 per day
Startup | November 13, 2021

DawaDost rolls out diabetes medicine at Re 1 per day

The start-up has announced the scheme to mark World Diabetes Day


FDA approves Cyltezo, the first interchangeable biosimilar to Humira
Drug Approval | October 20, 2021

FDA approves Cyltezo, the first interchangeable biosimilar to Humira

Second interchangeable biosimilar product approved by agency


IPM growth led by Covid  driven products to taper off in Q2FY22: Nirmal Bang
News | October 06, 2021

IPM growth led by Covid driven products to taper off in Q2FY22: Nirmal Bang

In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report


Biocon launches Everolimus tablets in the US
Drug Approval | October 04, 2021

Biocon launches Everolimus tablets in the US

According to IQVIA, US sales of Everolimus (Afinitor) tablets were approximately US $ 675 million in the 12 months ending July 2021


Lilly to transfer rights of two diabetes drugs to Cipla in India
Drug Approval | October 04, 2021

Lilly to transfer rights of two diabetes drugs to Cipla in India

Lilly will continue to maintain its existing operating model for the remaining portfolio of products